Improved Pathologic Diagnosis—Forecasting the Future in Glioblastoma

Improved Pathologic Diagnosis—Forecasting the Future in Glioblastoma

Bibliographic Details
Main Authors:	David J. Pisapia, Rajiv Magge, Rohan Ramakrishna
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2017-12-01
Series:	Frontiers in Neurology
Subjects:	glioblastoma GBM molecular diagnostics IDH mutation MGMT promotor whole exome sequencing
Online Access:	http://journal.frontiersin.org/article/10.3389/fneur.2017.00707/full

Similar Items

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
by: Combs Stephanie E, et al.
Published: (2011-09-01)

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
by: Yusuke Funakoshi, et al.
Published: (2021-05-01)

CHANGES IN THE MGMT GENE EXPRESSION IN PATIENTS WITH PRIMARY GLIOBLASTOMA AFTER RELAPSE. INFLUENCE OF CLINICAL CHARACTERISTICS AND MGMT EXPRESSION ON SURVIVAL OF PATIENTS
by: M. V. Matsko, et al.
Published: (2021-06-01)

Spatial progression and molecular heterogeneity of IDH-mutant glioblastoma determined by DNA methylation-based mapping
by: James F. Lyon, et al.
Published: (2021-06-01)

Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-Like Cells
by: Brandner, S., et al.
Published: (2022)

The distribution of isocitrate dehydrogenase mutations, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p/19q codeletion in different glioma subtypes and their correlation with glioma prognosis in Taiwanese population: A single center study
by: Peng-Wei Hsu, et al.
Published: (2021-03-01)

MORPHOLOGIC AND MOLECULAR FEATURES OF PRIMARY GLIOBLASTOMA IN PATIENTS SURVIVING MORE THAN 3 YEARS
by: M. V. Matsko, et al.
Published: (2019-06-01)

A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma
by: Thidathip Wongsurawat, et al.
Published: (2020-06-01)

The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas
by: Arne Christians, et al.
Published: (2019-10-01)

Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas
by: Kanish Mirchia, et al.
Published: (2020-07-01)

Genetic secrets of long-term glioblastoma survivors
by: Ivana Jovčevska
Published: (2018-08-01)

Integrated Analysis of the Clinical and Molecular Characteristics of IDH Wild-Type Gliomas in the Chinese Glioma Genome Atlas
by: Peng Wang, et al.
Published: (2021-07-01)

Isocitrate dehydrogenase 1 and 2 genes mutations and MGMT methylation in gliomas
by: D. V. Tabakov, et al.
Published: (2017-04-01)

The Personalisation of Glioblastoma Treatment Using Whole Exome Sequencing: A Pilot Study
by: Anne-Marie Garrett, et al.
Published: (2020-02-01)

Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features
by: Mingxiao Li, et al.
Published: (2021-04-01)

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
by: Miyuki Uno, et al.
Published: (2011-01-01)

Corrigendum: Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological and Molecular Features
by: Mingxiao Li, et al.
Published: (2021-05-01)

Changes of O<sup>6</sup>-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse—A Meta-Analysis Type Literature Review
by: Jonas Feldheim, et al.
Published: (2019-11-01)

Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma
by: Sebastian Stasik, et al.
Published: (2020-12-01)

Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience
by: Christoph Straube, et al.
Published: (2017-04-01)

Glioblastoma multiforme: etiology, progression, and treatment
by: Jindani, Rajika
Published: (2018)

Genetics and epigenetics of glioblastoma: applications and overall incidence of IDH1 mutation
by: Xuan eZong, et al.
Published: (2016-01-01)

Lomeguatrib Increases the Radiosensitivity of MGMT Unmethylated Human Glioblastoma Multiforme Cell Lines
by: Anna Kirstein, et al.
Published: (2021-06-01)

Glioblastoma and the significance of MGMT gene methylation
by: Payam Izadpanahi, et al.
Published: (2014-08-01)

Efficacy of Whole-Ventricular Radiotherapy in Patients Undergoing Maximal Tumor Resection for Glioblastomas Involving the Ventricle
by: Kyung Hwan Kim, et al.
Published: (2021-09-01)

Treatment options and outcomes for glioblastoma in the elderly patient
by: Arvold ND, et al.
Published: (2014-02-01)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
by: Fatih Incekara, et al.
Published: (2020-05-01)

Assessing Versatile Machine Learning Models for Glioma Radiogenomic Studies across Hospitals
by: Risa K. Kawaguchi, et al.
Published: (2021-07-01)

Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions
by: Krzysztof Roszkowski, et al.
Published: (2016-11-01)

Prognostic Significance of MGMT Promoter Methylation in Patients with Glioblastoma Undergoing Surgical Intervention: A Retrospective Study in Northeastern Iran
by: Kazem Anvari, et al.
Published: (2018-07-01)

Germline and somatic mutations in the pathology of pineal cyst: A whole‐exome sequencing study of 93 individuals
by: Yuanqing Yan, et al.
Published: (2021-06-01)

Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses
by: Yu-Qing Liu, et al.
Published: (2019-12-01)

A long non-coding RNA signature in glioblastoma multiforme predicts survival
by: Xiao-Qin Zhang, et al.
Published: (2013-10-01)

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
by: Josefine Radke, et al.
Published: (2019-06-01)

NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition
by: Cheng-Yu Tsai, et al.
Published: (2021-05-01)

Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins
by: Gaspar J. Kitange, et al.
Published: (2016-03-01)

Retrospective and Randomized Analysis of Influence and Correlation of Clinical and Molecular Prognostic Factors in a Mono-Operative Series of 122 Patients with Glioblastoma Treated with STR or GTR
by: Maurizio Salvati, et al.
Published: (2020-02-01)

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
by: Rui-Chao Chai, et al.
Published: (2019-09-01)

The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme
by: Anna Kirstein, et al.
Published: (2020-04-01)

Clinical Significance and Systematic Expression Analysis of the Thyroid Receptor Interacting Protein 13 (TRIP13) as Human Gliomas Biomarker
by: Ssu-Han Chen, et al.
Published: (2021-05-01)